In einer Phase-II-Studie wurden 30 Patientinnen mit metastasierendem Mammakarzinom und ungünstiger Prognose – davon 20 chemotherapeutisch nicht vorbehandelt und 10 vorbehandelt – mit der Kombination Adriamycin/Vindesin behandelt (ADM 60 mg/m2 Tag 1 i.v.; VDS 3-5 mg/m2 Tag 1 i.v.; Wiederholung alle 3-4 Wochen). Die Raten kompletter und partieller Remissionen betrugen bei vorbehandelten Patientinnen 20 % bei chemotherapeutisch nicht vorbehandelten Patientinnen 70%, die Remissionsdauern im Mittel 11 Monate. Noch befinden sich 5 Patientinnen in der Studie (4 × CR, 1 × PR). Kardiomyopathien traten nicht, ernste Leukopenien zweimal, beherrschbare, gastrointestinale Begleiterscheinungen und totale Alopezie fast immer auf. Eine Dosiserhöhung von 3 auf 5 mg/m2 Vindesin wurde in dieser Kombination nicht toleriert. Die Kombination ist rasch wirksam und gut praktikabel. In Adriamycinhaltigen Kombinationen kann Vincristin durch Vindesin ersetzt werden, wobei die geringe Neurotoxizität von Vindesin für dieses Medikament spricht.

Keywords:
Metastasierendes Mammakarzinom, Vindesin, Adriamycin, Chemotherapie
This content is only available via PDF.
© 1982 S. Karger AG, Basel
1982
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.